The Canadian government has outlined several options for skilled professionals. Immigration, Refugees and Citizenship Canada (IRCC), a department of the Government of Canada, has announced that the ...

The FDA fully approved iptacopan (Fabhalta) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, drugmaker Novartis announced on ...

Low complement is usually a pattern of immune-system use, not a diagnosis by itself. The safest interpretation depends on whether C3, C4, CH50, urine, kidney function, and autoimmune markers move ...

St. Mary’s Community Services recently celebrated its newest housing project with an open house. The nonprofit celebrated Pathways Neighborhood on Wednesday, June 17, at 545 W. Sonora St. in downtown ...

NEW YORK--(BUSINESS WIRE)--Pathway Labs today announced its public launch of EchoNext, the world’s first FDA-approved AI detection tool that reads standard 12-lead electrocardiograms (ECGs) to flag ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CANARY ISLANDS, Spain — The business model underpinning kids and family animation is under growing strain, as a post-streaming contraction collides with declining linear viewership and tighter ...

Complement pathway proteins are involved in immunoglobulin A-containing immune complex (IgA-IC) formation and deposition in the kidneys. Elevated complement factor H-related protein 1 (CFHR1) may be a ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Lizzy led STAT’s coverage of the FDA. Her ...

The new pathway aligns with health leaders' stated goal of reducing red tape for cell and gene therapies, but contrasts with the surprising recent rejections of ...